Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Hussey Copper , a leader in ... copper announces Pullman Regional Hospital,s conversion of more than ... touch surface, at a nominal cost.  This reasonably priced ... other bacteria within 2 hours of exposure 1 and ... infectious diseases in its facilities. Pullman Regional ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... July 22, 2014 Biofeedback ... disorder (ADHD) is diagnosed, selecting medication to best treat ... Analyzing brain patterns by using electroencephalography (EEG) can help ... thus lower the risk of adverse drug events. , ... Biomarkers” in the current issue of the journal ...
(Date:7/21/2014)... Hills, IL (PRWEB) July 21, 2014 ... control, and simple programming, the new Cole-Parmer® ... Head is easy to operate for automated ... cycles for hands-free dispensing. The batch count function ... cumulative volume or totalizer tracks amount dispensed across ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2
... E May Help,Prevent, Cardiovascular Events in Hp2-2 Diabetes, ... SYI ) today announced new data demonstrating that,discontinuation ... may result,in an increased risk of heart attack and ... at the Annual Scientific,Sessions of the American Heart Association, ...
... First laboratory to be certified for A1c testing using ... Heritage Labs,International LLC, a division of Hooper Holmes ... A1c testing methods by the National,Glycohemoglobin Standardization Program (NGSP)., ... hemoglobin A1c, one,for testing whole blood specimens and the ...
... 11 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... at the 5th Annual Lazard Capital Markets Healthcare,Conference in ... p.m. EST., A webcast and audio archive of ... at http://www.amicustherapeutics.com . Participants,should allow approximately five to ...
Cached Biology Technology:Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4Heritage Labs Announces A1c Test Certification Milestone 2Heritage Labs Announces A1c Test Certification Milestone 3
(Date:7/22/2014)... by researchers in modifying properties of nanomaterials for application ... thanks to recent innovative studies conducted by scientists from ... use of a simple, efficient and low cost technique ... led by Professor Sow Chorng Haur from the Department ... that the properties of two different types of materials ...
(Date:7/22/2014)... a cost-effectiveness analysis of commercial diet programs and pills, ... the best value for the money. The Jenny Craig ... the most expensive option tested, according to researchers at ... The findings, published in the June issue of the ... health and weight-loss benefits per dollar spent as insurance ...
(Date:7/22/2014)... multinational, collaborative effort, researchers from the Icahn School of ... locations in the human genome associated with the risk ... on any psychiatric disorder to date, conducted with 80,000 ... point to biological mechanisms and pathways that may underlie ... the disorder, which has seen little innovation in drug ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3
... have determined the fine-scale genetic structure of the first ... change. , They used a high-throughput sequencing technique called ... , Their results, which focus on the pitcher ... the journal Proceedings of the National Academy of ...
... of the High Arctic climate roughly 50 million years ago ... explain how ancient alligators and giant tortoises were able to ... as they endured six months of darkness each year. ... Eocene period 52 to 53 million years ago, also has ...
... Male infertility is a common medical problem, affecting millions ... include an inability to make productive sperm. Now, using ... of Pennsylvania School of Medicine are beginning to identify ... problem. Shelley Berger PhD, the Daniel S. ...
Cached Biology News:Genetic structure of first animal to show evolutionary response to climate change determined 2Genetic structure of first animal to show evolutionary response to climate change determined 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 2New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 4Swimming upstream: Molecular approaches to better understand male infertility 2Swimming upstream: Molecular approaches to better understand male infertility 3
...
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... Serial Analysis of Gene Expression (SAGE) ... technology. Agencourt offers a cost-effective outsourcing ... and LongSAGE libraries. Agencourt's SAGE sequencing ... project turnaround and long Phred20 read ...
... Affinity Life Sciences can provide custom microplate coating using advanced ... a variety of plate formats. We can also accommodate virtually ... range of 0.5-320 L):, , ... 96 well microplate, 384 ...
Biology Products: